Role of Adjuvant Radiotherapy in Atypical (WHO Grade II) and Anaplastic (WHO Grade III) Meningiomas: a Systematic Review

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2020 Jul 12

PMID 32651886

Citations 6

Authors

P D Delgado-Lopez

E M Corrales-Garcia

Affiliations

Soon will be listed here.

Abstract

The systematic adoption of the histopathologic criteria provided by the 2016 update of the WHO classification of brain tumors has markedly increased the relative proportion of atypical and anaplastic meningiomas. These tumors exhibit a much greater recurrence rate compared to benign meningiomas, which negatively impacts survival. In recent years, the publication of numerous retrospective case series, yet no randomized controlled trials, on the impact of radiation therapy in non-benign meningioma, has yielded conflicting evidence. At present, maximum safe resection, including the dural attachment, is the preferred primary treatment modality for all types of meningiomas. Adjuvant radiotherapy is currently recommended for subtotally resected grade II and for all grade III meningiomas. However, in grade II meningiomas achieving complete resection, close radiologic and clinical observation is a feasible option. Despite the great amount of non-benign meningiomas available and eligible for trials, there is a striking lack of prospective studies testing adjuvant therapies against observation for this subset of patients. An updated and systematic literature review is provided on the effectiveness and indications of radiotherapy on grade II and III meningiomas.

Citing Articles

The Role of Immunotherapy in the Treatment of Rare Central Nervous System Tumors.

Rodriguez A, Kamiya-Matsuoka C, Majd N Curr Oncol. 2023; 30(6):5279-5298.

PMID: 37366884 PMC: 10297279. DOI: 10.3390/curroncol30060401.

The "Combo" radiotherapy treatment for high-risk grade 2 meningiomas: dose escalation and initial safety and efficacy analysis.

Pontoriero A, Critelli P, Conti A, Cardali S, Angileri F, Germano A J Neurooncol. 2022; 161(2):203-214.

PMID: 35927392 DOI: 10.1007/s11060-022-04107-3.

Radiation therapy for atypical and anaplastic meningiomas: an overview of current results and controversial issues.

Vagnoni L, Aburas S, Giraffa M, Russo I, Chiarella V, Paolini S Neurosurg Rev. 2022; 45(5):3019-3033.

PMID: 35665867 PMC: 9492595. DOI: 10.1007/s10143-022-01806-3.

Multisession radiosurgery for grade 2 (WHO), high risk meningiomas. A phase II clinical trial.

Marchetti M, Pinzi V, Iezzoni C, Morlino S, Tramacere I, De Martin E J Neurooncol. 2022; 157(3):397-403.

PMID: 35378640 PMC: 8979484. DOI: 10.1007/s11060-022-03978-w.

DNA Methylation Associates With Clinical Courses of Atypical Meningiomas: A Matched Case-Control Study.

Millesi M, Ryba A, Hainfellner J, Roetzer T, Berghoff A, Preusser M Front Oncol. 2022; 12:811729.

PMID: 35356207 PMC: 8959647. DOI: 10.3389/fonc.2022.811729.

References

Dolecek T, Dressler E, Thakkar J, Liu M, Al-Qaisi A, Villano J . Epidemiology of meningiomas post-Public Law 107-206: The Benign Brain Tumor Cancer Registries Amendment Act. Cancer. 2015; 121(14):2400-10. PMC: 5549267. DOI: 10.1002/cncr.29379. View

Nakasu S, Fukami T, Jito J, Nozaki K . Recurrence and regrowth of benign meningiomas. Brain Tumor Pathol. 2009; 26(2):69-72. DOI: 10.1007/s10014-009-0251-2. View

Pearson B, Markert J, Fisher W, Guthrie B, Fiveash J, Palmer C . Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus. 2008; 24(5):E3. DOI: 10.3171/FOC/2008/24/5/E3. View

Bagshaw H, Burt L, Jensen R, Suneja G, Palmer C, Couldwell W . Adjuvant radiotherapy for atypical meningiomas. J Neurosurg. 2016; 126(6):1822-1828. DOI: 10.3171/2016.5.JNS152809. View

Zhi M, Girvigian M, Miller M, Chen J, Schumacher A, Rahimian J . Long-Term Outcomes of Newly Diagnosed Resected Atypical Meningiomas and the Role of Adjuvant Radiotherapy. World Neurosurg. 2018; 122:e1153-e1161. DOI: 10.1016/j.wneu.2018.11.006. View

Rogers L, Barani I, Chamberlain M, Kaley T, McDermott M, Raizer J . Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2014; 122(1):4-23. PMC: 5062955. DOI: 10.3171/2014.7.JNS131644. View

Sun S, Hawasli A, Huang J, Chicoine M, Kim A . An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas. Neurosurg Focus. 2015; 38(3):E3. DOI: 10.3171/2015.1.FOCUS14757. View

Winther T, Torp S . Significance of the Extent of Resection in Modern Neurosurgical Practice of World Health Organization Grade I Meningiomas. World Neurosurg. 2016; 99:104-110. DOI: 10.1016/j.wneu.2016.11.034. View

Marcus H, Price S, Wilby M, Santarius T, Kirollos R . Radiotherapy as an adjuvant in the management of intracranial meningiomas: are we practising evidence-based medicine?. Br J Neurosurg. 2008; 22(4):520-8. DOI: 10.1080/02688690802308687. View

10.

Zhu H, Bi W, Aizer A, Hua L, Tian M, Den J . Efficacy of adjuvant radiotherapy for atypical and anaplastic meningioma. Cancer Med. 2019; 8(1):13-20. PMC: 6346222. DOI: 10.1002/cam4.1531. View

11.

Hemmati S, Ghadjar P, Grun A, Badakhshi H, Zschaeck S, Senger C . Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma. Radiat Oncol. 2019; 14(1):160. PMC: 6719347. DOI: 10.1186/s13014-019-1368-z. View

12.

Kaur G, Sayegh E, Larson A, Bloch O, Madden M, Sun M . Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro Oncol. 2014; 16(5):628-36. PMC: 3984561. DOI: 10.1093/neuonc/nou025. View

13.

Jenkinson M, Waqar M, Farah J, Farrell M, Barbagallo G, McManus R . Early adjuvant radiotherapy in the treatment of atypical meningioma. J Clin Neurosci. 2016; 28:87-92. DOI: 10.1016/j.jocn.2015.09.021. View

14.

Hasan S, Young M, Albert T, Shah A, Okoye C, Bregy A . The role of adjuvant radiotherapy after gross total resection of atypical meningiomas. World Neurosurg. 2014; 83(5):808-15. DOI: 10.1016/j.wneu.2014.12.037. View

15.

Pereira B, de Almeida A, Paiva W, Teixeira M, Marie S . Impact of radiotherapy in atypical meningioma recurrence: literature review. Neurosurg Rev. 2018; 42(3):631-637. DOI: 10.1007/s10143-018-0959-8. View

16.

Keric N, Kalasauskas D, Freyschlag C, Gempt J, Misch M, Poplawski A . Impact of postoperative radiotherapy on recurrence of primary intracranial atypical meningiomas. J Neurooncol. 2020; 146(2):347-355. DOI: 10.1007/s11060-019-03382-x. View

17.

Li H, Zhang Y, Zhang G, Zhang G, Wang B, Li D . Treatment Protocol, Long-Term Follow-Up, and Predictors of Mortality in 302 Cases of Atypical Meningioma. World Neurosurg. 2018; 122:e1275-e1284. DOI: 10.1016/j.wneu.2018.11.032. View

18.

Zhang G, Zhang Y, Zhang G, Li D, Wu Z, Wang Y . Outcome and prognostic factors for atypical meningiomas after first recurrence. J Clin Neurosci. 2019; 63:100-105. DOI: 10.1016/j.jocn.2019.01.032. View

19.

Weber D, Ares C, Villa S, Peerdeman S, Renard L, Baumert B . Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042). Radiother Oncol. 2018; 128(2):260-265. DOI: 10.1016/j.radonc.2018.06.018. View

20.

Liu X, Shan B, Wang M, Xu J . World Health Organization Grade II Meningiomas: The Role of Adjuvant/Salvage Gamma Knife Surgery After Initial Surgery and Prognostic Factor Assessment. World Neurosurg. 2017; 109:e352-e362. DOI: 10.1016/j.wneu.2017.09.178. View